- Record: found
- Abstract: not found
- Article: not found
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti ,
Roger Echols ,
Yuko Matsunaga ,
Mari Ariyasu ,
Yohei Doi ,
Ricard Ferrer ,
Thomas P Lodise ,
Thierry Naas ,
Yoshihito Niki ,
David L Paterson ,
Simon Portsmouth ,
Julian Torre-Cisneros ,
Kiichiro Toyoizumi ,
Richard G Wunderink ,
Tsutae D Nagata
October 2020
October 2020
Read this article at
ScienceOpenPublisher
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d4311659e263">New antibiotics are needed for the treatment of
patients with life-threatening carbapenem-resistant
Gram-negative infections. We assessed the efficacy and safety of cefiderocol versus
best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
</p>